HealthMore in Health→
Bepirovirsen posts phase III gains in hepatitis B cure push
Phase III trial results reported in the New England Journal of Medicine showed roughly one in five chronic hepatitis B patients achieved a functional cure after 24 weeks of bepirovirsen.
Key Takeaways
- Two duplicate phase III trials reported functional cure rates of 20% and 19%.
- No patients in the placebo groups achieved a functional cure.
DE
DT Editorial Team··via medicalxpress.com